The Role of <EMPH TYPE="ITAL">APOE</EMF Risk Factors for Cognitive Decline in Elderly Persons

JAMA - Journal of the American Medical Association 282, 40

DOI: 10.1001/jama.282.1.40

Citation Report

#	Article	IF	CITATIONS
1	Stroke and Apolipoprotein E $\hat{l}\mu 4$ Are Independent Risk Factors for Cognitive Decline. Stroke, 2000, 31, 2431-2436.	2.0	82
2	A unifying hypothesis of Alzheimer's disease. III. Risk factors. Human Psychopharmacology, 2000, 15, 1-70.	1.5	38
3	Why is learning and memory dysfunction in Type 2 diabetes limited to older adults?. Diabetes/Metabolism Research and Reviews, 2000, 16, 308-315.	4.0	160
4	Homocysteine, Alzheimer's disease, and cognitive function. Nutrition, 2000, 16, 675-677.	2.4	63
5	Cognitive Function and Apolipoprotein E in Very Old Adults: Findings From the Nun Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2000, 55, S69-S75.	3.9	49
6	ls <i>APOE</i> -Îμ4 a risk factor for cognitive impairment in normal aging?. Neurology, 2000, 54, 2082-2088.	1.1	126
7	Education, Activity, Health, Blood Pressure and Apolipoprotein E as Predictors of Cognitive Change in Old Age: A Review. Gerontology, 2000, 46, 163-177.	2.8	322
8	Vascular risk factors for Alzheimer's disease:. Neurobiology of Aging, 2000, 21, 153-160.	3.1	618
9	EPIDEMIOLOGIC PRINCIPLES IN THE EVALUATION OF SUSPECTED NEUROTOXIC DISORDERS. Neurologic Clinics, 2000, 18, 631-648.	1.8	5
10	Circumscribed cognitive dysfunction in middle-aged adults with type 2 diabetes. Diabetes Care, 2000, 23, 1486-1493.	8.6	143
11	Untangling vascular dementia. Lancet, The, 2001, 358, 2097-2098.	13.7	46
12	Joint Effect of the <i>APOE </i> Gene and Midlife Systolic Blood Pressure on Late-Life Cognitive Impairment. Stroke, 2001, 32, 2882-2889.	2.0	126
13	Longitudinal Assessment of Neurocognitive Function after Coronary-Artery Bypass Surgery. New England Journal of Medicine, 2001, 344, 395-402.	27.0	2,259
14	The Relationship of <i>APOE</i> Genotype to Cognitive Functioning in Older Africanâ€American and Caucasian Community Residents. Journal of the American Geriatrics Society, 2001, 49, 1148-1155.	2.6	58
15	Estimation of bivariate measurements having different change points, with application to cognitive ageing. Statistics in Medicine, 2001, 20, 3695-3714.	1.6	77
16	Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Annals of Neurology, 2001, 49, 736-744.	5.3	54
17	Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease. Journal of Molecular Neuroscience, 2001, 17, 101-118.	2.3	449
18	Apolipoprotein E alleles in nonagenarian subjects in the Belfast Elderly Longitudinal Free-living Ageing Study (BELFAST). Mechanisms of Ageing and Development, 2001, 122, 1367-1372.	4.6	44

#	ARTICLE	IF	CITATIONS
19	Current perspectives on benefits and risks of hormone replacement therapy. American Journal of Obstetrics and Gynecology, 2001, 185, S13-S23.	1.3	61
20	Genetic predictors of perioperative neurological and cognitive injury and recovery. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2001, 15, 247-276.	4.0	4
21	Cognitive Effects of Standard-Dose Chemotherapy in Patients with Cancer. Cancer Investigation, 2001, 19, 812-820.	1.3	183
22	Association of Incident Alzheimer Disease and Blood Pressure Measured From 13 Years Before to 2 Years After Diagnosis in a Large Community Study. Archives of Neurology, 2001, 58, 1640.	4.5	191
23	Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology, 2001, 56, 42-48.	1.1	793
24	VLDL receptor polymorphism, cognitive impairment, and dementia. Neurology, 2001, 56, 1183-1188.	1.1	28
25	Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo Eâ€related disorders in humans. FASEB Journal, 2001, 15, 2623-2630.	0.5	135
26	Childhood socioeconomic position and cognitive function in adulthood. International Journal of Epidemiology, 2001, 30, 256-263.	1.9	279
27	Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease. Archives of Neurology, 2001, 58, 397-405.	4.5	1,532
28	Longitudinal Assessment of Neurocognitive Function after Coronary-Artery Bypass Surgery. New England Journal of Medicine, 2001, 344, 1876-1876.	27.0	1
29	Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. Journal of Medical Genetics, 2002, 39, 639-643.	3.2	51
30	Evidence for Genetic Mediation of Executive Control: A Study of Aging Male Twins. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2002, 57, P133-P143.	3.9	87
31	The apolipoprotein E varepsilon2 allele and decline in episodic memory. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 672-677.	1.9	144
32	Vascular disease and cognitive function in older men in the Caerphilly cohort. Age and Ageing, 2002, 31, 43-48.	1.6	63
33	Effects of alcohol and cigarette use on cognition in middle-aged adults. Journal of the International Neuropsychological Society, 2002, 8, 683-690.	1.8	15
34	Change in cognitive functioning associated with ApoE genotype in a community sample of older adults Psychology and Aging, 2002, 17, 194-208.	1.6	68
35	The Apolipoprotein E ϵ4 Allele and Decline in Different Cognitive Systems During a 6-Year Period. Archives of Neurology, 2002, 59, 1154.	4.5	208
36	Association between Blood Pressure and Cognitive Function in a Biracial Community Population of Older Persons. Neuroepidemiology, 2002, 21, 123-130.	2.3	96

3

#	Article	IF	CITATIONS
37	Complications of diabetes in elderly people. BMJ: British Medical Journal, 2002, 325, 916-917.	2.3	84
38	Homocysteine, vitamin B ₆ , and vascular disease in AD patients. Neurology, 2002, 58, 1471-1475.	1.1	171
39	Understanding Ageing: Further Commentary on the Limitations of Cross-Sectional Designs for Ageing Research. Gerontology, 2002, 48, 22-29.	2.8	45
40	Breast Cancer Chemotherapy-Related Cognitive Dysfunction. Clinical Breast Cancer, 2002, 3, S84-S90.	2.4	134
41	Apolipoprotein E ϵ4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease. Annals of Internal Medicine, 2002, 137, 149.	3.9	561
42	3MS normative data for the elderly. Archives of Clinical Neuropsychology, 2002, 17, 171-177.	0.5	24
43	Apolipoproteins and aging: emerging mechanisms. Ageing Research Reviews, 2002, $1,345-365$.	10.9	117
44	Vascular dementia revisited: Diagnosis, pathogenesis, treatment, and prevention. Medical Clinics of North America, 2002, 86, 477-499.	2.5	128
45	Selective nonâ€response to clinical assessment in the longitudinal study of aging: implications for estimating population levels of cognitive function and dementia. International Journal of Geriatric Psychiatry, 2002, 17, 704-709.	2.7	42
46	Apolipoprotein E ε4 allele is not associated with the cognitive impairment in communityâ€dwelling normal elderly individuals. International Journal of Geriatric Psychiatry, 2002, 17, 635-640.	2.7	35
47	Relationship of Race/Ethnicity and Blood Pressure to Change in Cognitive Function. Journal of the American Geriatrics Society, 2002, 50, 424-429.	2.6	76
48	Imaging Interactions between Alzheimer's Disease and Cerebrovascular Disease. Annals of the New York Academy of Sciences, 2002, 977, 403-410.	3.8	13
49	Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Current Neurology and Neuroscience Reports, 2003, 3, 215-222.	4.2	73
50	Cognitive efficiency declines over time in adults with Type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia, 2003, 46, 940-948.	6.3	217
51	The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Seminars in Oncology, 2003, 30, 749-762.	2.2	69
52	Prevalence of Dementia in Older Latinos: The Influence of Type 2 Diabetes Mellitus, Stroke and Genetic Factors. Journal of the American Geriatrics Society, 2003, 51, 169-177.	2.6	356
53	Age, Vascular Risk, and Cognitive Decline in an Older, British, African-Caribbean Population. Journal of the American Geriatrics Society, 2003, 51, 1547-1553.	2.6	39
54	The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 2003, 12, 612-619.	2.3	302

#	Article	IF	CITATIONS
56	Impact of diabetes on cognitive function among older Latinos. Journal of Clinical Epidemiology, 2003, 56, 686-693.	5.0	96
57	Negative Associations of Chronic Stress and Cognitive Performance in Older Adult Spouse Caregivers. Experimental Aging Research, 2003, 29, 303-318.	1.2	91
58	Serum lipids and memory in a population based cohort of middle age women. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1530-1535.	1.9	73
59	Prospective Study of Alcohol Consumption and Risk of Dementia in Older Adults. JAMA - Journal of the American Medical Association, 2003, 289, 1405.	7.4	395
61	Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia., 2003,, CD003804.		47
62	Apolipoprotein-E Influences Aspects of Intellectual Ability in Type 1 Diabetes. Diabetes, 2003, 52, 145-148.	0.6	23
63	Genetic Evidence for Cognitive Reserve: Variations in Memory and Related Cognitive Functions. Journal of Clinical and Experimental Neuropsychology, 2003, 25, 594-613.	1.3	47
64	Combined effects of <i>APOE</i> genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology, 2003, 61, 655-660.	1.1	71
65	Gender, cognitive decline, and risk of AD in older persons. Neurology, 2003, 60, 1777-1781.	1.1	147
66	Peripheral Arterial Disease and Cognitive Function. Psychosomatic Medicine, 2003, 65, 757-763.	2.0	56
67	Studies of aging, hypertension and cognitive functioning: With contributions from the Maine-Syracuse study. Advances in Cell Aging and Gerontology, 2003, 15, 89-131.	0.1	3
68	The Role of Cerebrovascular Disease in Dementia. Neurologist, 2003, 9, 123-136.	0.7	50
69	The role of <i>APOE</i> -ε4 in longitudinal cognitive decline. Neurology, 2003, 60, 1077-1081.	1.1	242
70	Modeling Memory Decline in Older Adults: The Importance of Preclinical Dementia, Attrition, and Chronological Age Psychology and Aging, 2003, 18, 658-671.	1.6	129
71	Introduction to the Special Section on Health and Cognitive Function Health Psychology, 2003, 22, 555-558.	1.6	19
72	Relation Between Cardiovascular and Metabolic Disease and Cognition in Very Old Age: Cross-Sectional and Longitudinal Findings From the Berlin Aging Study Health Psychology, 2003, 22, 559-569.	1.6	109
73	Role of white matter lesions, cerebrel atrophy, and APOE on cognition in older persons with and without dementia: The Cache County, Utah, study of memory and aging Neuropsychology, 2003, 17, 339-352.	1.3	37
74	Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology, 2004, 63, 658-663.	1.1	463

#	Article	IF	CITATIONS
75	Mixed Dementia. JAMA - Journal of the American Medical Association, 2004, 292, 2901.	7.4	293
76	APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology, 2004, 63, 816-821.	1.1	99
77	Association of APOE genotype with carotid atherosclerosis in men and women. Journal of Lipid Research, 2004, 45, 1868-1875.	4.2	77
78	Pathogenic Factors in Vascular Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2004, 18, 278-298.	1.5	16
79	Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology, 2004, 63, 1902-1907.	1.1	224
80	Genetic influences on memory performance in familial Alzheimer disease. Neurology, 2004, 62, 414-421.	1.1	33
81	Diabetes mellitus and risk of dementia in the Kungsholmen project. Neurology, 2004, 63, 1181-1186.	1.1	384
82	Cognitive Impairment in Chronic Kidney Disease. Journal of the American Geriatrics Society, 2004, 52, 1863-1869.	2.6	380
83	The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. European Journal of Pharmacology, 2004, 490, 169-175.	3.5	257
84	Can Dementia Be Prevented? Brain Aging in a Population-Based Context. Annual Review of Public Health, 2004, 25, 1-24.	17.4	153
85	Modeling Intraindividual Cognitive Change in Aging Adults: Results from the Einstein Aging Studies. Aging, Neuropsychology, and Cognition, 2004, 11, 196-211.	1.3	41
86	Vascular factors in dementia: an overview. Journal of the Neurological Sciences, 2004, 226, 19-23.	0.6	79
87	Subclinical Cardiovascular Disease in Older Adults: Insights From the Cardiovascular Health Study. The American Journal of Geriatric Cardiology, 2004, 13, 137-149.	0.6	63
88	Searching for genetic influences on normal cognitive ageing. Trends in Cognitive Sciences, 2004, 8, 178-184.	7.8	69
89	Progressive cognitive impairment after stroke. Journal of Stroke and Cerebrovascular Diseases, 2004, 13, 99-103.	1.6	15
90	Apolipoprotein E and Cognitive Performance: A Meta-Analysis Psychology and Aging, 2004, 19, 592-600.	1.6	386
91	The Impact of Childhood Intelligence on Later Life: Following Up the Scottish Mental Surveys of 1932 and 1947 Journal of Personality and Social Psychology, 2004, 86, 130-147.	2.8	693
92	Utilization of Cognitive Support in Episodic Free Recall as a Function of Apolipoprotein E and Vitamin Bâ,â,, or Folate Among Adults Aged 75 Years and Older Neuropsychology, 2004, 18, 362-370.	1.3	29

#	Article	IF	CITATIONS
94	Pathogenesis of Alzheimer Disease: Metabolic Factors., 2004,, 303-353.		O
95	Apolipoprotein E $\hat{l}\mu$ 4 Allele and Lorazepam Effects on Memory in High-Functioning Older Adults. Archives of General Psychiatry, 2005, 62, 209.	12.3	37
96	Educating Caregivers of Geriatric Rehabilitation Consumers. Topics in Geriatric Rehabilitation, 2005, 21, 263-274.	0.4	2
97	Psychophysiological Mediators of Caregiver Stress and Differential Cognitive Decline Psychology and Aging, 2005, 20, 402-411.	1.6	105
98	Estimating Age Change in List Recall in Asset and Health Dynamics of the Oldest-Old: The Effects of Attrition Bias and Missing Data Treatment Psychology and Aging, 2005, 20, 460-475.	1.6	11
99	Lower cognitive test scores observed in alcohol abstainers are associated with demographic, personality, and biological factors: the PATH Through Life Project. Addiction, 2005, 100, 1291-1301.	3.3	28
100	Dementia and Alzheimer's Disease Incidence in Relationship to Cardiovascular Disease in the Cardiovascular Health Study Cohort. Journal of the American Geriatrics Society, 2005, 53, 1101-1107.	2.6	425
101	The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurology, The, 2005, 4, 487-499.	10.2	971
102	Cognitive decline and dementia in diabetesâ€"systematic overview of prospective observational studies. Diabetologia, 2005, 48, 2460-2469.	6.3	852
103	APOE polymorphism, socioeconomic status and cognitive function in mid-life. Social Psychiatry and Psychiatric Epidemiology, 2005, 40, 557-563.	3.1	29
104	Diabetes and brain aging: Epidemiologic evidence. Current Diabetes Reports, 2005, 5, 59-63.	4.2	86
105	Glucoregulation has Greater Impact on Cognitive Performance than Macro-vascular Disease in Men with type 2 Diabetes: Data from the Caerphilly Study. European Journal of Epidemiology, 2005, 20, 761-768.	5.7	21
106	VASCULAR DEMENTIA AND ALZHEIMER'S DISEASE: THE UNSOLVED PROBLEM OF CLINICAL AND NEUROPSYCHOLOGICAL DIFFERENTIAL DIAGNOSIS. International Journal of Neuroscience, 2005, 115, 1657-1667.	1.6	6
107	Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. Neurology, 2005, 65, 107-112.	1.1	85
108	Central Obesity and the Aging Brain. Archives of Neurology, 2005, 62, 1545-8.	4.5	254
109	Sex Differences in the Clinical Manifestations of Alzheimer Disease Pathology. Archives of General Psychiatry, 2005, 62, 685.	12.3	455
110	Apolipoprotein E, B Vitamins, and Cognitive Function in Older Adults. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2005, 60, P41-P48.	3.9	21
111	Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology, 2005, 65, 876-881.	1.1	107

#	Article	IF	CITATIONS
112	Normal Aging of Brain Structure and Cognition: Evolutionary Perspectives. Research in Human Development, 2005, 2, 69-82.	1.3	0
113	Potential Mechanisms for Chemotherapy-Induced Impairments in Cognitive Function. Oncology Nursing Forum, 2005, 32, 1151-1163.	1.2	76
114	Chemotherapy-Induced Cognitive Impairment in Women With Breast Cancer: A Critique of the Literature. Oncology Nursing Forum, 2005, 32, 329-342.	1.2	34
115	Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. Journal of Lipid Research, 2005, 46, 949-968.	4.2	157
116	Blood Mercury Levels and Neurobehavioral Function. JAMA - Journal of the American Medical Association, 2005, 293, 1875.	7.4	89
117	<i>APOE</i> genotype and cognitive decline in a middle-aged cohort. Neurology, 2005, 64, 268-276.	1.1	134
118	Education modifies the effect of apolipoprotein epsilon 4 on cognitive decline. Neurobiology of Aging, 2005, 26, 17-24.	3.1	25
119	Developmental and vascular risk factors for Alzheimer's disease. Neurobiology of Aging, 2005, 26, 325-334.	3.1	118
120	Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiology of Aging, 2005, 26, 475-484.	3.1	59
121	Diabetes mellitus and dementia. Diabetes and Metabolism, 2006, 32, 403-414.	2.9	231
122	The NIH Cognitive and Emotional Health Project. Alzheimer's and Dementia, 2006, 2, 12-32.	0.8	272
123	Dementia and Cerebrovascular Disease. Mayo Clinic Proceedings, 2006, 81, 223-230.	3.0	67
124	Design and Analysis of Longitudinal Studies on Aging. , 2006, , 15-37.		43
125	The Primary Care of Alzheimer Disease. American Journal of the Medical Sciences, 2006, 332, 314-333.	1.1	9
127	Prevention of AD: the Which, When, and on Whom?. Alzheimer Disease and Associated Disorders, 2006, 20, S75-S78.	1.3	4
128	Ankle Brachial Index as a Predictor of Cognitive Impairment in the General Population: Ten-Year Follow-Up of the Edinburgh Artery Study. Journal of the American Geriatrics Society, 2006, 54, 763-769.	2.6	48
129	Cardiovascular disease and Alzheimer's disease: common links. Journal of Internal Medicine, 2006, 260, 211-223.	6.0	260
130	The quest for genetic determinants of human longevity: challenges and insights. Nature Reviews Genetics, 2006, 7, 436-448.	16.3	455

#	Article	IF	CITATIONS
131	The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia, 2006, 49, 2015-2023.	6.3	112
132	Genetic determinants of exceptional human longevity: insights from the Okinawa Centenarian Study. Age, 2006, 28, 313-332.	3.0	77
133	Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging. Experimental Gerontology, 2006, 41, 619-627.	2.8	75
134	Diabetes, leukoencephalopathy and rage. Neurobiology of Disease, 2006, 23, 445-461.	4.4	91
135	Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Annals of Neurology, 2006, 59, 673-681.	5.3	220
136	Cerebrovascular disease, APOEϵ4 allele and cognitive decline in a cognitively normal population. Neurological Research, 2006, 28, 650-656.	1.3	22
137	Association Between Serum Beta-Carotene Levels and Decline of Cognitive Function in High-Functioning Older Persons With or Without Apolipoprotein E 4 Alleles: MacArthur Studies of Successful Aging. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 616-620.	3.6	47
138	Relationship between Lifetime Smoking, Smoking Status at Older Age and Human Cognitive Function. Neuroepidemiology, 2006, 26, 83-92.	2.3	43
139	Familial Alzheimer disease in Latinos: Interaction between APOE, stroke, and estrogen replacement. Neurology, 2006, 66, 35-40.	1.1	52
140	Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia. Current Neuropharmacology, 2006, 4, 87-100.	2.9	39
141	Patterns of Cognitive Performance in Middle-Aged and Older Adults: A Cluster Analytic Examination. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 59-64.	2.3	72
142	Apolipoprotein E Â4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 902-908.	1.9	43
143	Adiposity and Alzheimers Disease. Current Alzheimer Research, 2007, 4, 127-134.	1.4	65
144	ApoE-Â4 is associated with reduced memory in long-standing intractable temporal lobe epilepsy. Neurology, 2007, 68, 409-414.	1.1	49
145	Cerebrovascular disease and dementia. British Journal of Radiology, 2007, 80, S121-S127.	2.2	55
147	Hypertension, Cognitive Impairment and Dementia: An Epidemiological Perspective. Current Hypertension Reviews, 2007, 3, 166-176.	0.9	23
148	Brain Structure and Function Differences in Monozygotic Twins: Possible Effects of Breast Cancer Chemotherapy. Journal of Clinical Oncology, 2007, 25, 3866-3870.	1.6	233
149	Apolipoprotein E Gene and Age-Related Maculopathy in Older Individuals. JAMA Ophthalmology, 2007, 125, 68.	2.4	31

#	Article	IF	CITATIONS
150	Circulating Interleukin-15 in Dementia Disorders. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 318-325.	1.8	11
151	Cardiovascular Diseases and Decline in Cognitive Function in an Elderly Community Population: The Edinburgh Artery Study. Psychosomatic Medicine, 2007, 69, 425-434.	2.0	56
152	Cholesterol and Triglycerides Moderate the Effect of Apolipoprotein E on Memory Functioning in Older Adults. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2007, 62, P112-P118.	3.9	57
153	Cerebrovascular risk factors do not contribute to genetic variance of cognitive function. Neurobiology of Aging, 2007, 28, 735-741.	3.1	21
154	Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort. Archives of Clinical Neuropsychology, 2007, 22, 405-414.	0.5	5
155	Interaction between genes and environment in neurodegenerative diseases. Comptes Rendus - Biologies, 2007, 330, 318-328.	0.2	62
156	Ankle-to-Brachial Index and Dementia. Circulation, 2007, 116, 2269-2274.	1.6	77
157	Cognitive impairment in heart failure: A systematic review of the literature. European Journal of Heart Failure, 2007, 9, 440-449.	7.1	445
158	Demenze vascolari. EMC - Neurologia, 2007, 7, 1-11.	0.0	0
159	Atherosclerosis and dementia: Leading by association. Annals of Neurology, 2007, 61, 377-379.	5.3	0
160	Cognitive dysfunction associated with metabolic syndrome. Obesity Reviews, 2007, 8, 409-418.	6.5	71
161	Microalbuminuria is a negative correlate for cognitive function in older adults with peripheral arterial disease: results from the U.S. National Health and Nutrition Examination Survey 1999–2002. Journal of Internal Medicine, 2007, 262, 562-570.	6.0	32
162	Profile of Cognitive Impairment in Chronic Heart Failure. Journal of the American Geriatrics Society, 2007, 55, 1764-1770.	2.6	160
163	Association Between Apolipoprotein E ₄ and Cognitive Decline in Elderly Adults. Journal of the American Geriatrics Society, 2007, 55, 1777-1785.	2.6	120
164	The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): Rationale, Design, and Methods. American Journal of Cardiology, 2007, 99, S112-S122.	1.6	105
165	Type 2 diabetes and risk of cognitive impairment and dementia. Current Neurology and Neuroscience Reports, 2007, 7, 373-380.	4.2	164
166	Type 2 diabetes and cognitive impairment: The Edinburgh Type 2 Diabetes Study. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2008, 25, 132-134.	0.2	1
167	Fat intake at midlife and cognitive impairment later in life: a populationâ€based CAIDE study. International Journal of Geriatric Psychiatry, 2008, 23, 741-747.	2.7	266

#	Article	IF	CITATIONS
168	Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease. European Journal of Pharmacology, 2008, 585, 119-129.	3.5	144
169	Cardiovascular risk factors in centenarians. Experimental Gerontology, 2008, 43, 106-113.	2.8	60
171	New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly. Drugs and Aging, 2008, 25, 913-925.	2.7	61
172	Homocysteine and cognitive performance: Modification by the ApoE genotype. Neuroscience Letters, 2008, 430, 64-69.	2.1	46
173	Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline. Journal of Clinical Epidemiology, 2008, 61, 1018-1027.e9.	5.0	102
174	C-reactive protein and rate of dementia in carriers and non carriers of Apolipoprotein APOE4 genotype. Neurobiology of Aging, 2008, 29, 1774-1782.	3.1	54
175	Dementia Prevention: Methodological Explanations for Inconsistent Results. Epidemiologic Reviews, 2008, 30, 35-66.	3.5	145
176	Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE $\hat{l}\mu 4$. Archives of Neurology, 2008, 65, 89-93.	4.5	263
177	Homocysteine and C-Reactive Protein Are Not Markers of Cognitive Impairment in Patients with Major Cardiovascular Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 309-316.	1.5	8
178	Apolipoprotein E ε4 Allele Genotype and the Effect of Depressive Symptoms on the Risk of Dementia in Men. Archives of General Psychiatry, 2008, 65, 906.	12.3	78
179	Vascular factors and prevention of dementia. International Review of Psychiatry, 2008, 20, 344-356.	2.8	39
180	Apolipoprotein E Genotype, Cortisol, and Cognitive Function in Community-Dwelling Older Adults. American Journal of Psychiatry, 2008, 165, 1456-1464.	7.2	80
181	Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2008, 4, 865.	2.2	101
182	Diabetes and the Risk of Multi-System Aging Phenotypes: A Systematic Review and Meta-Analysis. PLoS ONE, 2009, 4, e4144.	2.5	315
183	Apolipoprotein E Genotype Modifies the Association between Midlife Lung Function and Cognitive Function in Old Age. Dementia and Geriatric Cognitive Disorders, 2009, 28, 418-426.	1.5	18
184	Depressed Mood Mediates Decline in Cognitive Processing Speed in Caregivers. Gerontologist, The, 2009, 49, 12-22.	3.9	86
185	Diabetes as a Risk Factor for Cognitive Decline in Older Patients. Dementia and Geriatric Cognitive Disorders, 2009, 27, 24-33.	1.5	43
186	Diabetes: Vascular or Neurodegenerative: An Epidemiologic Perspective. Stroke, 2009, 40, S53-S55.	2.0	27

#	Article	IF	CITATIONS
187	Carotid Intimal Medial Thickness Predicts Cognitive Decline Among Adults Without Clinical Vascular Disease. Stroke, 2009, 40, 3180-3185.	2.0	136
188	Peripheral arterial disease and cognitive function. Vascular Medicine, 2009, 14, 51-61.	1.5	61
189	Vitamin B-12, apolipoprotein E genotype, and cognitive performance in community-living older adults: evidence of a gene-micronutrient interaction. American Journal of Clinical Nutrition, 2009, 89, 1263-1268.	4.7	59
190	Using Generalized Estimating Equations to Analyze Longitudinal Data in Nursing Research. Western Journal of Nursing Research, 2009, 31, 948-964.	1.4	20
191	The influence of age on the association between cholesterol and cognitive function. Experimental Gerontology, 2009, 44, 112-122.	2.8	63
192	Presence of the APOE ε4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine–Syracuse Study. Diabetologia, 2009, 52, 2551-2560.	6.3	76
193	Olfaction in Aging and Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1170, 647-657.	3.8	36
194	Vitamin E and Memory: Is It Vascular Protection?. Nutrition Reviews, 2009, 58, 109-111.	5.8	2
195	Rate of MMSE score change in Alzheimer's disease: Influence of education and vascular risk factors. Clinical Neurology and Neurosurgery, 2009, 111, 327-330.	1.4	90
196	Challenges in phenotype definition in the whole-genome era: multivariate models of memory and intelligence. Neuroscience, 2009, 164, 88-107.	2.3	51
197	Blood pressure and the risk for dementia—A double edged sword. Ageing Research Reviews, 2009, 8, 61-70.	10.9	152
198	Cognitive function and hypertension. Journal of Human Hypertension, 2009, 23, 86-96.	2.2	126
199	Fourteenâ€year longitudinal study of vascular risk factors, <i>APOE</i> genotype, and cognition: The ARIC MRI Study. Alzheimer's and Dementia, 2009, 5, 207-214.	0.8	199
200	Adiposity and Alzheimer's disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 15-21.	2.5	130
201	Adiposity, Type 2 Diabetes, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 693-704.	2.6	195
202	Apolipoprotein $\ddot{l}\mu4$ status is associated with behavioral symptoms in nursing home residents with dementia. International Psychogeriatrics, 2009, 21, 722-728.	1.0	18
203	Early Age-Related Macular Degeneration, Cognitive Function, and Dementia. JAMA Ophthalmology, 2009, 127, 667.	2.4	103
204	Systematic Review: Factors Associated With Risk for and Possible Prevention of Cognitive Decline in Later Life. Annals of Internal Medicine, 2010, 153, 182.	3.9	552

#	Article	IF	CITATIONS
205	Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. Neuroscience and Biobehavioral Reviews, 2010, 34, 408-437.	6.1	19
206	Cognitive dysfunction in patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2010, 26, 507-519.	4.0	201
207	<i>APOE</i> predicts amyloidâ€beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology, 2010, 67, 122-131.	5. 3	727
208	Relationship between the diagnostic components of metabolic syndrome (MS) and cognition by ApoE genotype in the elderly. Archives of Gerontology and Geriatrics, 2010, 50, 69-72.	3.0	23
209	Comparison of ankle-brachial pressure index and pulse wave velocity as markers of cognitive function in a community-dwelling population. BMC Psychiatry, 2010, 10, 46.	2.6	26
210	Can Statins Prevent Dementia in Older Adults?. Journal of the American Geriatrics Society, 2010, 58, 1393-1394.	2.6	2
211	The Aging Mind: Vascular Health in Normal Cognitive Aging. Journal of the American Geriatrics Society, 2010, 58, S319-24.	2.6	34
213	Vascular Risk Factors: Imaging and Neuropathologic Correlates. Journal of Alzheimer's Disease, 2010, 20, 699-709.	2.6	104
214	Applications of Neurocognitive Assessment in Behavioral Medicine., 2010,, 125-136.		1
215	Diabetes Is Associated with Increased Rate of Cognitive Decline in Questionably Demented Elderly. Dementia and Geriatric Cognitive Disorders, 2010, 29, 68-74.	1.5	55
216	Ankleâ€"brachial index predicts level of, but not change in, cognitive function: The Edinburgh Artery Study at the 15-year follow-up. Vascular Medicine, 2010, 15, 91-97.	1.5	21
218	Diabetes, Insulin and Alzheimer's Disease. Research and Perspectives in Alzheimer's Disease, 2010, , .	0.1	7
219	Vascular health, diabetes, APOE and dementia: the Aging, Demographics, and Memory Study. Alzheimer's Research and Therapy, 2010, 2, 19.	6.2	19
220	Inflammation and Genetics: An Insight in the Centenarian Model. Human Biology, 2011, 83, 531-559.	0.2	25
221	Successful Cognitive Aging. Current Topics in Behavioral Neurosciences, 2011, 10, 35-50.	1.7	43
222	Vascular Contributions to Cognitive Impairment and Dementia. Stroke, 2011, 42, 2672-2713.	2.0	2,989
223	Omega-3 fatty acids and cognitive decline: modulation by ApoEε4 allele and depression. Neurobiology of Aging, 2011, 32, 2317.e13-2317.e22.	3.1	74
224	Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases. Experimental Neurology, 2011, 230, 27-34.	4.1	127

#	Article	IF	CITATIONS
225	Ankle-brachial index as a marker of cognitive impairment and dementia in general population. A systematic review. Atherosclerosis, 2011, 216, 251-257.	0.8	65
226	Knowing Me, Knowing You: Can a Knowledge of Risk Factors for Alzheimer's Disease Prove Useful in Understanding the Pathogenesis of Parkinson's Disease?. Journal of Alzheimer's Disease, 2011, 25, 395-415.	2.6	24
227	Influences of APOE $\hat{l}\mu4$ and expertise on performance of older pilots Psychology and Aging, 2011, 26, 480-487.	1.6	9
228	Neighborhood Psychosocial Environment, Apolipoprotein E Genotype, and Cognitive Function in Older Adults. Archives of General Psychiatry, 2011, 68, 314.	12.3	41
229	Impact of cardiovascular risk factors on cognitive function: The Troms \tilde{A}_s study. European Journal of Neurology, 2011, 18, 737-743.	3.3	79
230	Subclinical carotid atherosclerosis and cognitive function. Acta Neurologica Scandinavica, 2011, 124, 18-22.	2.1	22
231	Do the effects of APOE- E4 on cognitive function and decline depend upon vitamin status? Macarthur studies of successful aging. Journal of Nutrition, Health and Aging, 2011, 15, 196-201.	3.3	18
232	Synergistic associations of depression and apolipoprotein E genotype with incidence of dementia. International Journal of Geriatric Psychiatry, 2011, 26, 893-898.	2.7	29
233	The association of diabetes and dementia and possible implications for nondiabetic populations. Expert Review of Neurotherapeutics, 2011, 11, 1609-1617.	2.8	40
234	Impact of Common KIBRA Allele on Human Cognitive Functions. Neuropsychopharmacology, 2011, 36, 1296-1304.	5.4	34
235	Glutamatergic Neurons in Rodent Models Respond to Nanoscale Particulate Urban Air Pollutants <i>in Vivo</i> and <i>in Vitro</i> Environmental Health Perspectives, 2011, 119, 1003-1009.	6.0	174
236	Cerebrovascular risk factors and preclinical memory decline in healthy <i>APOE</i> ε4 homozygotes. Neurology, 2011, 76, 1078-1084.	1.1	58
237	Diabetes and the elderly brain: sweet memories?. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 189-196.	3.2	22
238	Apolipoprotein E Genotype: The Innocent Bystander or Active Bridge Between Metabolic Syndrome and Cognitive Impairment?. Journal of Alzheimer's Disease, 2012, 30, S283-S304.	2.6	4
239	Age-related differences in episodic memory: A synergistic contribution of genetic and physiological vascular risk factors Neuropsychology, 2012, 26, 442-450.	1.3	19
240	Modeling the Dementia Epidemic. CNS Neuroscience and Therapeutics, 2012, 18, 175-181.	3.9	9
241	Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiology of Aging, 2012, 33, 827.e11-827.e19.	3.1	109
242	A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiology of Aging, 2012, 33, 1017.e1-1017.e15.	3.1	160

#	Article	IF	CITATIONS
243	Alzheimer Mechanisms and Therapeutic Strategies. Cell, 2012, 148, 1204-1222.	28.9	1,548
244	Copper and iron in Alzheimer's disease: a systematic review and its dietary implications. British Journal of Nutrition, 2012, 107, 7-19.	2.3	69
245	Carotid Atherosclerosis Predicts Lower Cognitive Test Results: A 7-Year Follow-Up Study of 4,371 Stroke-Free Subjects – The TromsÃ, Study. Cerebrovascular Diseases, 2012, 33, 159-165.	1.7	68
246	Genotype patterns at <i>PICALM, CR1, BIN1, CLU</i> , and <i>APOE</i> genes are associated with episodic memory. Neurology, 2012, 78, 1464-1471.	1.1	95
247	Appraisal of cognition in preclinical Alzheimer's disease: a conceptual review. Neurodegenerative Disease Management, 2012, 2, 183-195.	2.2	20
248	APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921. Molecular Psychiatry, 2012, 17, 315-324.	7.9	143
249	Age-related differences in memory and executive functions in healthy APOE É-4 carriers: The contribution of individual differences in prefrontal volumes and systolic blood pressure. Neuropsychologia, 2012, 50, 704-714.	1.6	45
250	Social disorder, APOE-E4 genotype, and change in cognitive function among older adults living in Chicago. Social Science and Medicine, 2012, 74, 1584-1590.	3.8	41
251	Carotid artery plaque progression and cognitive decline: the <scp>T</scp> romsÃ, Study 1994–2008. European Journal of Neurology, 2012, 19, 1318-1324.	3.3	23
252	Untreated Hypertension Decreases Heritability of Cognition in Late Middle Age. Behavior Genetics, 2012, 42, 107-120.	2.1	10
253	Association between asymptomatic carotid stenosis and cognitive function: A systematic review. Neuroscience and Biobehavioral Reviews, 2013, 37, 1493-1499.	6.1	46
254	APOE Genotype Modifies the Relationship between Midlife Vascular Risk Factors and Later Cognitive Decline. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 1361-1369.	1.6	95
255	The forgotten APOE allele: A review of the evidence and suggested mechanisms for the protective effect of APOE É>2. Neuroscience and Biobehavioral Reviews, 2013, 37, 2878-2886.	6.1	157
256	Metabolic Syndrome and Amnestic Mild Cognitive Impairment: Singapore Longitudinal Ageing Study-2 Findings. Journal of Alzheimer's Disease, 2013, 34, 649-657.	2.6	52
257	Clinical and Subclinical Macrovascular Disease as Predictors of Cognitive Decline in Older Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2779-2786.	8.6	65
258	Can lifestyle modification improve neurocognition? Rationale and design of the ENLIGHTEN clinical trial. Contemporary Clinical Trials, 2013, 34, 60-69.	1.8	18
259	Cognitive Function in an Elderly Population. Psychosomatic Medicine, 2013, 75, 20-29.	2.0	57
260	Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology, 2013, 9, 106-118.	10.1	2,482

#	Article	IF	Citations
261	Differential effect of <i>APOE</i> genotype on amyloid load and glucose metabolism in AD dementia. Neurology, 2013, 80, 359-365.	1.1	99
262	Risk Factors for β-Amyloid Deposition in Healthy Aging. JAMA Neurology, 2013, 70, 600.	9.0	216
263	Atrial fibrillation and cognitive decline. Neurology, 2013, 81, 119-125.	1.1	180
264	Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. Age and Ageing, 2013, 42, 338-345.	1.6	136
265	Correlates of cognitive impairment in older Vietnamese. Aging and Mental Health, 2013, 17, 915-923.	2.8	13
266	Principal components methods for narrowâ€sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 770-778.	1.7	1
267	Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE $\hat{l}\mu 4$ Carriers. Journal of Alzheimer's Disease, 2013, 36, 563-570.	2.6	19
268	The Interaction of Age and Type 2 Diabetes on Executive Function and Memory in Persons Aged 35 Years or Older. PLoS ONE, 2013, 8, e82991.	2.5	22
270	Alzheimer's disease and periodontitis - an elusive link. Revista Da Associação Médica Brasileira, 2014, 60, 173-180.	0.7	37
271	Randomized controlled trial to evaluate the effect of canola oil on blood vessel function in peripheral arterial disease: rationale and design of the Canola-PAD Study. Open Access Journal of Clinical Trials, 2014, , 117.	1.5	0
272	Causes of Neurodegeneration in Diabetes: Possible Culprits and Therapeutic Targets. Brain Disorders & Therapy, 2014, 03, .	0.1	9
273	Potential Therapeutic Strategies for Alzheimer's Disease Targeting or Beyond <i>β</i> Amyloid: Insights from Clinical Trials. BioMed Research International, 2014, 2014, 1-22.	1.9	61
274	IDE (rs6583817) polymorphism and pulse pressure are independently and interactively associated with level and change in executive function in older adults Psychology and Aging, 2014, 29, 418-430.	1.6	26
275	NT-proBNP, blood pressure, and cognitive decline in the oldest old. Neurology, 2014, 83, 1192-1199.	1.1	28
276	Midlife Cardiovascular Risk Impacts Executive Function. Alzheimer Disease and Associated Disorders, 2014, 28, 16-22.	1.3	38
277	Atrial Fibrillation and Cognitive Decline–The Role of Subclinical Cerebral Infarcts. Stroke, 2014, 45, 2568-2574.	2.0	103
278	Expression of human apolipoprotein E4 reduces insulinâ€receptor substrate 1 expression and Akt phosphorylation in the ageing liver. FEBS Open Bio, 2014, 4, 260-265.	2.3	6
279	The ApoE4 genotype modifies the relationship of long-term glycemic control with cognitive functioning in elderly with type 2 diabetes. European Neuropsychopharmacology, 2014, 24, 1303-1308.	0.7	15

#	Article	IF	CITATIONS
280	Cognitive disorders in diabetic patients. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 126, 145-166.	1.8	18
281	Interaction of APOE genotype and testosterone on episodic memory in middle-aged men. Neurobiology of Aging, 2014, 35, 1778.e1-1778.e8.	3.1	23
282	Lower ankle-brachial index is related to worse cognitive performance in old age Neuropsychology, 2014, 28, 281-289.	1.3	16
283	Predictors of Retest Effects in a Longitudinal Study of Cognitive Aging in a Diverse Community-Based Sample. Journal of the International Neuropsychological Society, 2015, 21, 506-518.	1.8	30
284	Blood pressure interacts with APOE $\hat{l}\mu 4$ to predict memory performance in a midlife sample Neuropsychology, 2015, 29, 693-702.	1.3	14
285	Reduced phosphorylation of brain insulin receptor substrate and Akt proteins in apolipoprotein-E4 targeted replacement mice. Scientific Reports, 2015, 4, 3754.	3.3	37
286	Midlife Hypertension Risk and Cognition inÂthe Non-Demented Oldest Old: Framingham Heart Study. Journal of Alzheimer's Disease, 2015, 47, 197-204.	2.6	10
287	ApoE Type 4 Allele Affects Cognitive Function of Aged Population in Tianjin City, China. American Journal of Alzheimer's Disease and Other Dementias, 2015, 30, 503-507.	1.9	4
288	Les complications cérébrales du diabétique âgé. Medecine Des Maladies Metaboliques, 2015, 9, 701-7	′0 7 1	0
289	Associations Between Ankle-Brachial Index and Cognitive Function: Results From the Lifestyle Interventions and Independence for Elders Trial. Journal of the American Medical Directors Association, 2015, 16, 682-689.	2.5	17
290	<i>Apolipoprotein E</i> and <i>Clusterin</i> can magnify effects of personality vulnerability on declarative memory performance in nonâ€demented older adults. International Journal of Geriatric Psychiatry, 2016, 31, 502-509.	2.7	12
291	Alzheimer's Disease Risk Genes and Lipid Regulators. Journal of Alzheimer's Disease, 2016, 53, 15-29.	2.6	53
292	Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2016, 53, 1553-1562.	2.6	23
293	Subclinical carotid atherosclerosis and neurocognitive function in an urban population. Atherosclerosis, 2016, 249, 125-131.	0.8	17
294	Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension, 2016, 68, e67-e94.	2.7	482
295	Cognitive Impairment Among the Aging Population in a Community in Southwest Nigeria. Health Education and Behavior, 2016, 43, 93S-99S.	2.5	5
296	The role of APOE in cerebrovascular dysfunction. Acta Neuropathologica, 2016, 131, 709-723.	7.7	161
297	Serum apolipoprotein E is associated with long-term risk of Alzheimer's disease: The Rotterdam Study. Neuroscience Letters, 2016, 617, 139-142.	2.1	25

#	Article	IF	CITATIONS
298	Cognitive Decline in a Colombian Kindred With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2016, 73, 431.	9.0	69
299	Dexmedetomidine reduces postoperative delirium after joint replacement in elderly patients with mild cognitive impairment. Aging Clinical and Experimental Research, 2016, 28, 729-736.	2.9	64
300	The neuropathology and cerebrovascular mechanisms of dementia. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 172-186.	4.3	307
301	Two distinct classes of degenerative change are independently linked to clinical progression in mild cognitive impairment. Neurobiology of Aging, 2017, 54, 1-9.	3.1	18
302	Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review. Current Hypertension Reports, 2017, 19, 24.	3.5	278
303	Peripheral Inflammation, <i> Apolipoprotein E4 </i> , and Amyloid- \hat{l}^2 Interact to Induce Cognitive and Cerebrovascular Dysfunction. ASN Neuro, 2017, 9, 175909141771920.	2.7	54
304	Effects of Diabetes Mellitus on Cognitive Decline in Patients with Alzheimer Disease: A Systematic Review. Canadian Journal of Diabetes, 2017, 41, 114-119.	0.8	49
305	Altered Neuronal Activity Topography Markers in the Elderly with Increased Atherosclerosis. Frontiers in Aging Neuroscience, 2017, 9, 216.	3.4	5
306	Obesity Accelerates Alzheimer-Related Pathology in <i>APOE4</i> but not <i>APOE3</i> Mice. ENeuro, 2017, 4, ENEURO.0077-17.2017.	1.9	70
307	Association of Atrial Fibrillation With Cognitive Decline and Dementia Over 20ÂYears: The ARICâ€NCS (Atherosclerosis Risk in Communities Neurocognitive Study). Journal of the American Heart Association, 2018, 7, .	3.7	104
308	Human Apolipoprotein E Genotype Differentially Affects Olfactory Behavior and Sensory Physiology in Mice. Neuroscience, 2018, 380, 103-110.	2.3	15
309	APOE genotype and cognition in healthy individuals at risk of Alzheimer's disease: AÂreview. Cortex, 2018, 104, 103-123.	2.4	135
310	Blood pressure and risk of incident Alzheimer's disease dementia by antihypertensive medications and APOE ε4 allele. Annals of Neurology, 2018, 83, 935-944.	5. 3	21
311	Neighborhoods, sleep quality, and cognitive decline: Does where you live and how well you sleep matter?. Alzheimer's and Dementia, 2018, 14, 454-461.	0.8	15
312	Apolipoprotein E genotype impact on memory and attention in older persons: the moderating role of personality phenotype. International Journal of Geriatric Psychiatry, 2018, 33, 332-339.	2.7	5
313	Apolipoprotein E genotypes among diverse middle-aged and older Latinos: Study of Latinos-Investigation of Neurocognitive Aging results (HCHS/SOL). Scientific Reports, 2018, 8, 17578.	3.3	26
314	CLINICAL APPLICATION OF APOE IN ALZHEIMER'S PREVENTION: A PRECISION MEDICINE APPROACH. journal of prevention of Alzheimer's disease, The, 2018, 5, 1-7.	2.7	31
315	Inflammation as a central mechanism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 575-590.	3.7	1,254

#	Article	IF	CITATIONS
316	Atherosclerosis, Hypertension, and Diabetes in Alzheimer's Disease, Vascular Dementia, and Mixed Dementia: Prevalence and Presentation. Journal of Alzheimer's Disease, 2018, 65, 1247-1258.	2.6	49
317	Cross-Sectional Associations Between Cardiac Biomarkers, Cognitive Performance, and Structural Brain Changes Are Modified by Age. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1948-1958.	2.4	13
318	Carotid circumferential wall stress is not associated with cognitive performance among individuals in late middle age: The Maastricht Study. Atherosclerosis, 2018, 276, 15-22.	0.8	7
319	Gene Transfer Induced Hypercholesterolemia in Amyloid Mice. Journal of Alzheimer's Disease, 2018, 65, 1079-1086.	2.6	2
320	Interaction between apolipoprotein E genotype and hypertension on cognitive function in older women in the Nurses' Health Study. PLoS ONE, 2019, 14, e0224975.	2.5	9
321	Secular trends in cognitive trajectories of diverse older adults. Alzheimer's and Dementia, 2019, 15, 1576-1587.	0.8	21
322	Diabetes-Associated Dementia Risk and Competing Risk of Death in the Three-City Study. Journal of Alzheimer's Disease, 2019, 71, 1339-1350.	2.6	6
323	Association Between Periodontitis and Cognitive Impairment in Adults: A Systematic Review. Frontiers in Neurology, 2019, 10, 323.	2.4	30
324	Factors Associated with the Prevalence of Cognitive Impairment in a Rural Elderly Cameroonian Population: A Community-Based Study in Sub-Saharan Africa. Dementia and Geriatric Cognitive Disorders, 2019, 47, 104-113.	1.5	21
325	Ambient Air Pollution, Noise, and Late-Life Cognitive Decline and Dementia Risk. Annual Review of Public Health, 2019, 40, 203-220.	17.4	102
326	Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center. Journal of Alzheimer's Disease, 2019, 68, 145-158.	2.6	56
327	Associations Between Midlife (but Not Late-Life) Elevated Coronary Heart Disease Risk and Lower Cognitive Performance: Results From the Framingham Offspring Study. American Journal of Epidemiology, 2019, 188, 2175-2187.	3.4	12
328	Associations between neighborhood built environment and cognition vary by apolipoprotein E genotype: Multi-Ethnic Study of Atherosclerosis. Health and Place, 2019, 60, 102188.	3.3	21
329	Exosome Production Is Key to Neuronal Endosomal Pathway Integrity in Neurodegenerative Diseases. Frontiers in Neuroscience, 2019, 13, 1347.	2.8	49
330	Cardiovascular health, genetic risk, and risk of dementia in the Framingham Heart Study. Neurology, 2020, 95, e1341-e1350.	1.1	37
331	APOE ε4 and the Influence of Sex, Age, Vascular Risk Factors, and Ethnicity on Cognitive Decline. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1863-1873.	3.6	23
332	Long-term cognitive decline and mortality after carotid endarterectomy. Clinical Neurology and Neurosurgery, 2020, 194, 105823.	1.4	0
333	Physical activity and cognitive function: between-person and within-person associations and moderators. Aging, Neuropsychology, and Cognition, 2021, 28, 392-417.	1.3	13

#	Article	IF	Citations
334	Apolipoprotein E (APOE) $\hat{l}\mu 4$ Status Moderates the Relationship Between Close-Range Blast Exposure and Cognitive Functioning. Journal of the International Neuropsychological Society, 2021, 27, 315-328.	1.8	6
335	Aerobic exercise improves hippocampal blood flow for hypertensive Apolipoprotein E4 carriers. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2026-2037.	4.3	24
336	Gender-specific clinical risk scores incorporating blood pressure variability for predicting incident dementia. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 335-347.	4.4	11
337	Vascular mild cognitive impairment and its relationship to hemoglobin A1c levels and apolipoprotein E genotypes in the Dominican Republic. Dementia E Neuropsychologia, 2021, 15, 69-78.	0.8	0
338	Synergistic influence of education and marriage on the risk for cognition loss among the older people in China. Nursing Open, 2021, 8, 2616-2621.	2.4	3
339	Hemostatic factor levels and cognitive decline in older adults: The Cardiovascular Health Study. Journal of Thrombosis and Haemostasis, 2021, 19, 1219-1227.	3.8	3
340	Cholesterol, Atherosclerosis, and APOE in Vascular Contributions to Cognitive Impairment and Dementia (VCID): Potential Mechanisms and Therapy. Frontiers in Aging Neuroscience, 2021, 13, 647990.	3.4	31
341	Vigorous Physical Activity and Cognitive Trajectory Later in Life: Prospective Association and Interaction by Apolipoprotein E e4 in the Nurses' Health Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 817-825.	3.6	5
342	Hypertension and Hypercholesterolemia Modify Dementia Risk in Relation to APOE É,4 Status. Journal of Alzheimer's Disease, 2021, 81, 1493-1504.	2.6	8
343	Apolipoprotein E (APOE) $\hat{l}\mu 4$ moderates the relationship between c-reactive protein, cognitive functioning, and white matter integrity. Brain, Behavior, and Immunity, 2021, 95, 84-95.	4.1	6
344	Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e171-e191.	1.6	229
347	Cardiovascular Disease and Neurocognitive Function. , 2010, , 69-99.		6
348	Cognition in Type 2 Diabetes or Pre-diabetic Stages. , 2009, , 295-322.		6
349	The Relationship Between the Continuum of Elevated Adiposity, Hyperinsulinemia, and Type 2 Diabetes and Late-onset Alzheimer's Disease: An Epidemiological Perspective. Research and Perspectives in Alzheimer's Disease, 2010, , 89-107.	0.1	3
350	Vascular Risk Factors for Alzheimer's Disease. , 2000, , 43-58.		1
351	Glucocorticoids and the Aging Brain: Cause or Consequence?., 2001,, 883-905.		6
353	Demographic, health, cognitive, and sensory variables as predictors of mortality in very old adults Psychology and Aging, 2001, 16, 3-11.	1.6	161
354	Preexisting Cognitive Impairment and Mild Cognitive Impairment in Subjects Presenting for Total Hip Joint Replacement. Anesthesiology, 2011, 114, 1297-1304.	2.5	76

#	Article	IF	Citations
355	Update on Alzheimer's disease: recent findings and treatments. Western Journal of Medicine, 2000, 172, 115-120.	0.3	10
356	Is Alzheimer's disease inevitable with age?. Journal of Clinical Investigation, 1999, 104, 1171-1173.	8.2	47
358	The neuronal functions of human apolipoprotein E. OA Biochemistry, 2013, 1, .	0.1	2
359	Associations between arterial stiffening and brain structure, perfusion, and cognition in the Whitehall II Imaging Sub-study: A retrospective cohort study. PLoS Medicine, 2020, 17, e1003467.	8.4	19
360	Apolipoprotein C3 Polymorphisms, Cognitive Function and Diabetes in Caribbean Origin Hispanics. PLoS ONE, 2009, 4, e5465.	2.5	18
361	Automated Bayesian Segmentation of Microvascular White-Matter Lesions in the ACCORD-MIND Study. Advances in Medical Sciences, 2008, 53, 182-90.	2.1	21
362	Therapeutic approaches to age-associated neurocognitive disorders. Dialogues in Clinical Neuroscience, 2001, 3, 191-213.	3.7	7
363	Mild cognitive impairment: historical development and summary of research. Dialogues in Clinical Neuroscience, 2004, 6, 351-367.	3.7	42
364	Hypertension and the Risk of Dementia. Frontiers in Cardiovascular Medicine, 2020, 7, 5.	2.4	90
365	Biological Basis for Sleep Disturbance and Behavioral Symptoms in Dementia: A Biobehavioral Model. Research in Gerontological Nursing, 2011, 4, 281-293.	0.6	5
366	Effect of Prunus domestica L. (mirabelle) on learning and memory in mice. Ancient Science of Life: Journal of International Institute of Ayurveda, 2013, 32, 139.	0.3	9
367	Opportunities and Challenges for Interdisciplinary Research., 0,, 3-31.		3
368	The relationship of montreal cognitive assessment scores to framingham coronary and stroke risk scores. Open Journal of Psychiatry, 2011, 01, 49-55.	0.6	5
369	Apolipoprotein E4 Genotype and Depressive Symptoms as Risk Factors for Dementia in an Older Korean Population. Psychiatry Investigation, 2010, 7, 135.	1.6	29
370	Brain Aging (Normal): Behavioral, Cognitive, and Personality Consequences., 2001,, 1318-1321.		0
372	Organisch bedingte StĶrungen. , 2002, , 189-216.		0
373	DEMENTIA FROM BRAIN VASCULAR DISEASE: THE SILENT EPIDEMIC. , 2003, , .		0
374	Alzheimer's Disease and Vascular Dementia. , 2004, , 103-130.		0

#	Article	IF	CITATIONS
375	Understanding Cognition in the Elderly. The Consultant Pharmacist, 2004, 19, 487-494.	0.4	0
376	Diabetes and Hypertension. , 2009, , 191-202.		0
377	L2 English Receptive and Productive Vocabulary in Senior Learners. ITL - International Journal of Applied Linguistics (Belgium), 2010, 160, 112-131.	1.4	3
378	Diabetes and the Brain $\hat{a} \in \text{``An Epidemiologic Perspective. Research and Perspectives in Alzheimer's Disease, 2010, , 73-80.}$	0.1	0
379	Genetic Factors and Adult Mortality. International Handbooks of Population, 2011, , 399-410.	0.5	1
380	Apo E gene polymorphism in patients with metabolic syndrome and cognitive disorders. Arterial Hypertension (Russian Federation), 2012, 18, 421-428.	0.4	2
381	Alzheimer′s Disease and Type 2 Diabetes Mellitus: Risk Factors and Effectiveness of Antidiabetic Agents in Treatment of Alzheimer′s Disease. Science Journal of Clinical Medicine, 2013, 2, 114.	0.1	2
382	Cardiovascular Disease and Neurocognitive Function. , 2019, , 99-134.		0
383	Behavioral Symptoms of Dementia in Latinos: Pharmacological, Non-pharmacological, and Ethnocultural Healthcare Interventions. , 2020, , 187-203.		0
384	Diabetes and Hypertension. , 2020, , 283-302.		0
387	Dementia, quantitative neuroimaging, and apolipoprotein E genotype. American Journal of Neuroradiology, 2000, 21, 1857-68.	2.4	46
388	Association of ankle-brachial index with cognitive decline in patients with lacunar infarction. PLoS ONE, 2022, 17, e0263525.	2.5	1
389	Dynamics of the Brain Functional Network Associated With Subjective Cognitive Decline and Its Relationship to Apolipoprotein E â,¬4 Alleles. Frontiers in Aging Neuroscience, 2022, 14, 806032.	3.4	2
390	Association between Apoïµ4 allele and cardiometabolic and social risk factors with cognitive impairment in elderly population from Bogota. Dementia E Neuropsychologia, 2021, 15, 497-509.	0.8	0
393	Role of Hypertension and Hyperlipidemia in the Pathogenesis of Dementia., 2022,, 251-272.		1
394	Vascular pathology and pathogenesis of cognitive impairment and dementia in older adults. Cerebral Circulation - Cognition and Behavior, 2022, 3, 100148.	0.9	6
395	Ankle-Brachial Index and Cardio-Ankle Vascular Index as Predictors of Cognitive Decline Over Time After Carotid Endarterectomy. Cureus, 2022, , .	0.5	1
396	Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function. Nature Neuroscience, 2022, 25, 1020-1033.	14.8	57

#	ARTICLE	IF	CITATIONS
397	Cardiovascular Disease and Cognitive Function. , 2022, , 1363-1391.		0
398	Influence of Baseline Diastolic Blood Pressure on the Effects of Systolic Blood Pressure Lowering on Cognitive Function in Type 2 Diabetes Mellitus. American Journal of Hypertension, 2023, 36, 120-125.	2.0	1
399	A combination of midlife diabetes mellitus and the apolipoprotein E $\hat{l}\mu4$ allele increase risk for cognitive decline. Frontiers in Aging Neuroscience, 0, 14, .	3.4	1
400	Type 2 diabetes mellitus and cognitive function: understanding the connections. Current Opinion in Endocrinology, Diabetes and Obesity, 2023, 30, 7-13.	2.3	12
401	Interactions between the apolipoprotein E4 gene and modifiable risk factors for cognitive impairment: a nationally representative panel study. BMC Geriatrics, 2022, 22, .	2.7	1
402	Pulse Pressure Is Associated with Rapid Cognitive Decline over 4 Years: A Population-Based Cohort Study. Brain Sciences, 2022, 12, 1691.	2.3	1
403	Cell non-autonomous regulation of cerebrovascular aging processes by the somatotropic axis. Frontiers in Endocrinology, 0, 14 , .	3.5	9
406	Lower mortality risk in APOE4 carriers with normal cognitive ageing. Scientific Reports, 2023, 13, .	3.3	1
407	Citicoline May Prevent Cognitive Decline in Patients with Cerebrovascular Disease. Clinical Interventions in Aging, 0, Volume 18, 1093-1102.	2.9	0
408	Associations of ApoE Polymorphisms with Postoperative Atrial Fibrillation and Cardiac Injury in Patients with Coronary Artery Bypass Graft Surgery. International Heart Journal, 2023, 64, 1049-1053.	1.0	0
409	Cognitive Dysfunction and Exercise: From Epigenetic to Genetic Molecular Mechanisms. Molecular Neurobiology, 0, , .	4.0	0